

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		ATTY. DOCKET NO. 10071-037-999		APPLICATION NO. Unassigned 10/669,258			
			APPLICANT R. WILLIAMS et al.				
		FILING DATE 25 Sept 03		GROUP 1614			
		Concurrently herewith		1615			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,461,600 B1	10/2002	Ford	424	78.02	
	AB	6,387,957 B1	5/2002	Frome	514	647	
	AC	6,255,302 B1	7/2001	Kelly et al.	514	217.05	
	AD	6,251,948 B1	6/2001	Weber et al.	514	634	
	AE	6,251,903 B1	6/2001	Cai et al.	514	249	
	AF	6,245,781 B1	6/2001	Upadhyay et al.	514	321	
	AG	6,242,448 B1	6/2001	Kelly et al.	514	254.02	
	AH	6,239,194 B1	5/2001	Standke et al.	523	200	
	AI	6,225,324 B1	5/2001	Poss et al.	514	316	
	AJ	6,218,391 B1	4/2001	Arvanitis et al.	514	242	
	AK	6,211,171 B1	4/2001	Sawynok et al.	514	211.13	
	AL	6,197,830 B1	3/2001	Frome	514	654	
	AM	6,191,165 B1	2/2001	Ognyanov et al.	514	523	
	AN	6,191,131 B1	2/2001	He et al.	514	246	
	AO	6,174,192 B1	1/2001	Watanabe et al.	439	377	
	AP	6,172,097 B1	1/2001	Cordi et al.	514	396	
	AQ	6,133,282	10/2000	Horvath et al.	514	292	
	AR	6,117,855	9/2000	Carlson et al.	514	90	
	AS	6,096,771	8/2000	Kojima et al.	514	379	
	AT	6,025,369	2/2000	Rosenquist et al.	514	311	
	AU	6,017,961	1/2000	Flores et al.	514	561	
	AV	6,004,964	12/1999	Farrar et al.	514	255	
	AW	5,985,586	11/1999	Daggett et al.	435	7.21	
	AX	5,981,513	11/1999	Kruse et al.	514	91	
	AY	5,962,477	10/1999	Mak	514	327	
	AZ	5,948,389	9/1999	Stein	424	45	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (03/18/2009)

/Leslie A. Roysds/ (03/18/2009)

BB	5,944,403	6/1999	Nichols et al.	546	162	
BC	5,888,494	3/1999	Farrar et al.	424	78.05	
BD	5,869,521	2/1999	Farrar et al.	514	422	
BE	5,863,916	1/1999	Cai et al.	514	249	
BF	5,849,762	12/1998	Farrar et al.	414	327	
BG	5,834,465	11/1998	Olney	514	226.2	
BH	5,817,699	10/1998	Flores et al.	514	647	
BI	5,811,078	9/1998	Maycock et al.	424	45	
BJ	5,798,093	8/1998	Farrar et al.	424	45	
BK	5,783,700	7/1998	Nichols et al.	546	162	
BL	5,763,445	6/1998	Kruse et al.	514	255	
BM	5,760,023	6/1998	Farrar et al.	514	150	
BN	5,744,458	4/1998	Kruse et al.	514	91	
BO	5,708,168	1/1998	Keana et al.	540	520	
BP	5,688,955	11/1997	Kruse et al.	546	276.4	
BQ	5,667,773	9/1997	Farrar et al.	424	78.05	
BR	5,648,396	7/1997	Young et al.	514	651	
BS	5,646,151	7/1997	Kruse et al.	514	255	
BT	4,989,607	2/1991	Keusch et al.	128	640	
BU	4,920,101	4/1990	Minaskanian et al.	514	24	
BV	4,808,414	2/1989	Peck et al.	424	449	
BW	4,801,586	1/1989	Minaskanian et al.	514	212	
BX	4,755,535	7/1988	Minaskanian et al.	514	947	
BY	4,751,087	6/1988	Wick	424	449	
BZ	4,615,699	10/1986	Gale et al.	604	897	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	CA	WO 95/23798	9/1995	PCT				
	CB	WO 95/18124	6/1995	PCT				
	CC	WO 95/16679	6/1995	PCT				
	CD	WO 94/13677	6/1994	PCT				
	CE	WO 94/13676	6/1994	PCT				
	CF	WO 94/13661	6/1994	PCT				
	CG	WO 94/13644	6/1994	PCT				
	CH	WO 94/13643	6/1994	PCT				
	CI	0 577 394 A1	1/1994	Europe				
	CJ	WO 93/10163	5/1993	PCT				
	CK	0 107 376 A1	5/1984	Europe				

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (03/18/2009)

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

CL	"Handbook of Pharmaceutical Excipients," Edited by Arthur H. Kibbe, Ph.D., Am. Pharm. Assoc., 3:292-294, 2000.
CM	J. Sawynok et al., "Peripheral Antinociceptive Action of Amitriptyline in the Rat Formalin Test: Involvement of Adenosine," <i>Pain</i> , 80:45-55, 1999.
CN	J. Sawynok et al., "Peripheral Antinociceptive Actions of Desipramine and Fluoxetine in an Inflammatory and Neuropathic Pain Test in the Rat," <i>Pain</i> , 82:149-158, 1999.
CO	"Cardinal Manifestations and Presentations of Diseases," <i>Harrison's Principles of Internal Medicine</i> , Edited by A. Fauci et al., 14:1:53-58, 1998.
CP	C. Stein et al., "Peripheral Morphine Analgesia," <i>Pain</i> , 71:119-121, 1997.
CQ	T. Ghosh et al., Transdermal and Topical Drug Delivery Systems, "Types of Dermal Drug Delivery," <i>Interpharm Press, Inc.</i> , p. 7, 1997.
CR	T. Ghosh et al., Transdermal and Topical Drug Delivery Systems, "Transdermal and Dermal Therapeutic Systems," <i>Interpharm Press, Inc.</i> , pp. 87-93, 1997.
CS	T. Ghosh et al., Transdermal and Topical Drug Delivery Systems, "Transdermal and Dermal Therapeutic Systems: Current Status," <i>Interpharm Press, Inc.</i> , p. 33-112, 1997.
CT	Goodman & Gilman's The Pharmacological Basis of Therapeutics, Edited by J. Hardman et al., "Chapter 23 Opioid Analgesics and Antagonists," 9:521-525, 1996.
CU	Goodman & Gilman's The Pharmacological Basis of Therapeutics, Edited by J. Hardman et al., "Chapter 23 Opioid Analgesics and Antagonists," 9:529, 1996.
CV	Gennaro, Remington: The Science and Practice of Pharmacy, "Coarse Dispersions," 19(1):289, 1995.
CW	Wolfe et al., "Massive Dextromethorphan Ingestion and Abuse," <i>Am J. Emerg Med.</i> , 13:174-176, 1995.
CX	Jia-He Li et al., "Potent, Orally Active, Competitive N-Methyl-D-aspartate (NMDA) Receptor Antagonists Are Substrates for a Neutral Amino Acid Uptake System in Chinese Hamster Ovary Cells," <i>J. Med. Chem.</i> , 38:1955-1965, 1995.
CY	Olney et al., "NMDA Antagonists as Neurotherapeutic Drugs, Psychotogens, Neurotoxins, and Research Tools for Studying Schizophrenia," <i>Neuropsychopharmacology</i> , 13(4):335-345, 1995.
CZ	Yoneda et al., "Differential Profiles of Binding of a Radiolabeled Agonist and Antagonist at a Glycine Recognition Domain on the N-Methyl-D-Aspartate Receptor Ionophore Complex in Rat Brain," <i>J. Neurochem.</i> , 62(1):102-112, 1994.
DA	N. Michalun et al., "Milady's Skin Care and Cosmetic Ingredients Dictionary," Milady Publishing Company, p. 242, 1994.
DB	Bigge, "Structural Requirements for the Development of Potent N-Methyl-D-Aspartic Acid (NMDA) Receptor Antagonists," <i>Biochem. Pharmacol.</i> , 45(8):1547-1561, 1993.
DC	T. Ghosh et al., "Methods of Enhancement of Transdermal Drug Delivery: Part IIA, Chemical Permeation Enhancers," <i>Pharm. Tech.</i> , 17:62-90, 1993.
DD	T. Ghosh et al., "Methods of Enhancement of Transdermal Drug Delivery: Part IIB, Chemical Permeation Enhancers," <i>Pharm. Tech.</i> , 17:68-76, 1993.
DE	P. Leeson, "Glycine-Site N-Methyl-D-Aspartate Receptor Antagonists," <i>Drug Design for Neuroscience</i> , pp. 338-381, 1993.
DF	Wong et al., "Norfluoxetine Enantiomers as Inhibitors of Serotonin Uptake in Rat Brain," <i>Neuropsychopharmacology</i> , 8(4):337-344, 1993.
DG	Albers et al., "Tolerability of Oral Dextromethorphan in Patients With a History of Brain Ischemia," <i>Clinical Neuropharmacology</i> , 15(6):509-514, 1992.

DI	Steinberg et al., "Dextromethorphan Alters Cerebral Blood Flow and Protects Against Cerebral Injury Following Focal Ischemia," <u>Neuroscience Letters</u> , 133:225-228 , 1991.
DJ	Meldrum et al., "Excitatory Amino Acid Neurotoxicity and Neurodegenerative Disease," <u>TIPS</u> , 11:379-387 , 1990.
EK	Willems et al., "The Behavioral Pharmacology of NMDA Receptor Antagonists," <u>TIPS</u> , 11:423-428 , 1990.
DL	"Percutaneous Absorption," edited by R. Bronaugh et al., 2 nd Ed., Contents, 1989.
DM	Mayer et al., "Sites of Antagonist Action on N-Methyl-D-Aspartic Acid Receptors Studied Using Fluctuation Analysis and a Rapid Perfusion Technique," <u>Journal of Neurophysiology</u> , 60(2):645-663 , 1988.
DN	Thurkauf et al., "Synthesis, Absolute Configuration, and Molecular Modeling Study of Etoxadrol, a Potent Phencyclidine-Like Agonist," <u>J. Med. Chem.</u> , 31:2257-2263 , 1988.
DO	G. Eccleston, "Emulsions," Encyclopedia of Pharmaceutical Technology, edited by J. Swarbrick et al., 5:137-189 , 1988.
DP	J. Dohner, "Development of Processes and Equipment for Rate-Controlled Transdermal Therapeutic Systems," Transdermal Controlled Systemic Medications, edited by Y. Chien, pp 349-364 , 1987.
DQ	H. Wolff et al., "Development of Processes and Technology for Adhesive-Type Transdermal Therapeutic Systems," Transdermal Controlled Systemic Medications, edited by Y. Chien, pp 365-378 , 1987.
DR	D. Bova et al., "Product Development and Technology Transfer for Transdermal Therapeutic Systems," Transdermal Controlled Systemic Medications, edited by Y. Chien, pp 379-396 , 1987.
DS	A. Jacobson et al., "Enantiomeric and Diastereomeric Dioxadrols: Behavioral, Biochemical and Chemical Determination of the Configuration Necessary for Phencyclidine-Like Properties," <u>J. Pharmacol. Exp. Ther. P.</u> , 243(1):110-117 , 1987.
DT	M. Rogawski, "Therapeutic Potential of Excitatory Amino Acid Antagonists: Channel Blockers and 2,3-Benzodiazepines," <u>TIPS</u> , 14:325-331 , 1993.
DU	Grimwood et al., "Characterization of the Binding of [³ H]-689,560, An Antagonist for the Glycine Site on the N-Methyl-D-Aspartate Receptor, to Rat Brain Membranes," <u>Molecular Pharmacology</u> , 41:923-930 , 1992.
DV	Skolnick et al., "Monoaminergic Involvement in the Pharmacological Actions of Buspirone," <u>Br. J. Pharmac.</u> , 86:637-644 , 1985.
DW	Wong et al., "A New Inhibitor of Norepinephrine Uptake Devoid of Affinity for Receptors in Rat Brain," <u>J. Pharm. Exp. Therap.</u> , 222(1):61-65 , 1982.
DX	Kinemuchi et al., "Substrate Selectivity of Type A and Type B Monoamine Oxidase in Rat Brain," <u>J. Neurochem.</u> , 35(1):109-115 , 1980.
DY	W. Griffin, "Classification of Surface-Active Agents by "HLB," <u>J. Soc. Cosme. Chem.</u> , 31:326 , 1949.

EXAMINER	/Leslie A. Royds/ (03/18/2009)	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		